Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte(TM) Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

Stock Information for Soligenix Inc.

Loading

Please wait while we load your information from QuoteMedia.